{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:23Z","timestamp":1792601123460,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03817-8","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:16:50Z","timestamp":1792599410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Budesonide\/Glycopyrronium\/Formoterol Initiation on Healthcare Resource Utilization and Estimated Associated Costs and Greenhouse Gas Emissions Across COPD Care in Spain (ORESTES* Study)"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct06321731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-1172","authenticated-orcid":false,"given":"Juan Marco","family":"Figueira-Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-9366","authenticated-orcid":false,"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0957-5958","authenticated-orcid":false,"given":"Alba","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0790-1225","authenticated-orcid":false,"given":"Teresa","family":"Lastres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9124-7150","authenticated-orcid":false,"given":"Fernando","family":"de Andr\u00e9s-Nogales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0260-360X","authenticated-orcid":false,"given":"Carmen","family":"Corregidor-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5249","authenticated-orcid":false,"given":"Eunice","family":"Fitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-3669","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"S\u00e1nchez-Covisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"3817_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03361-x","author":"B Alc\u00e1zar-Navarrete","year":"2025","unstructured":"Alc\u00e1zar-Navarrete B, Figueira-Gon\u00e7alves JM, Corregidor-Garc\u00eda C, Fitas E, S\u00e1nchez-Covisa J, M\u00e1rquez-Mart\u00edn E, et al. Real-world outcomes in patients with COPD initiating budesonide\/glycopyrronium\/formoterol fumarate dehydrate in Spain: ORESTES study. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03361-x.","journal-title":"Adv Ther"},{"key":"3817_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-026-00341-6","author":"JM Figueira-Gon\u00e7alves","year":"2026","unstructured":"Figueira-Gon\u00e7alves JM, Alc\u00e1zar-Navarrete B, Casitas-Mateo R, Gonz\u00e1lez J, Gotera-Rivera CM, Herrej\u00f3n-Silvestre A, et al. Real-world outcomes in patients with COPD initiating budesonide\/glycopyrronium\/formoterol fumarate dihydrate after dual and triple therapy in Spain: a sub-study of the ORESTES study. Pulm Ther. 2026. https:\/\/doi.org\/10.1007\/s41030-026-00341-6.","journal-title":"Pulm Ther"},{"key":"3817_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-026-00366-x","author":"B Alc\u00e1zar-Navarrete","year":"2026","unstructured":"Alc\u00e1zar-Navarrete B, Figueira-Gon\u00e7alves JM, Blanco Cid N, Bruguera Avila N, Bernabeu Mora R, Fuster Gomila A, et al. Real-world outcomes across baseline risk profiles in patients with COPD initiating budesonide\/glycopyrronium\/formoterol fumarate dihydrate in Spain: insights from the ORESTES study. Pulm Ther. 2026. https:\/\/doi.org\/10.1007\/s41030-026-00366-x.","journal-title":"Pulm Ther"},{"key":"3817_CR4","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Mart\u00ednez N, Ancochea A, Lastres T, Torres C, Corregidor-Garc\u00eda C, S\u00e1nchez-Covisa J, Figueira-Gon\u00e7alves JM, Alc\u00e1zar-Navarrete B. Abstract: Impact of budesonide-glycopyrronium formoterol initiation on healthcare resource utilization and carbon emissions in patients with COPD in Spain: insights from the ORESTES study. ISPOR Europe 2025; Glasgow, Scotland; 2025.","DOI":"10.1016\/j.jval.2025.09.908"},{"issue":"11","key":"3817_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","volume":"206","author":"B Celli","year":"2022","unstructured":"Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206(11):1317\u201325.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3817_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","volume":"10","author":"D Adeloye","year":"2019","unstructured":"Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2019;10(5):447\u201358.","journal-title":"Lancet Respir Med"},{"issue":"10513","key":"3817_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(25)01917-8","volume":"406","author":"M Naghavi","year":"2025","unstructured":"GBD 2023, C.O.D.C., Naghavi M, Kyu HH, Hay S, Pisoni E. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1811\u201372.","journal-title":"Lancet"},{"issue":"1","key":"3817_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-03051-2","volume":"26","author":"Z Wang","year":"1990","unstructured":"Wang Z, Lin J, Liang L, Huang F, Yao X, Peng K, et al. Global, regional, and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021. Respir Res. 1990;26(1):2.","journal-title":"Respir Res"},{"issue":"1","key":"3817_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.arbres.2020.07.024","volume":"57","author":"JB Soriano","year":"2021","unstructured":"Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-Catalu\u00f1a JJ, Garc\u00eda-R\u00edo F, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol. 2021;57(1):61\u20139.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"3817_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24719-z","volume":"12","author":"JV Lazarus","year":"2019","unstructured":"Lazarus JV, Ortiz A, Tyrovolas S, Fern\u00e1ndez E, Guy D, White TM, et al. A GBD 2019 study of health and Sustainable Development Goal gains and forecasts to 2030 in Spain. Sci Rep. 2019;12(1):21154.","journal-title":"Sci Rep"},{"key":"3817_CR11","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2026 report). Global Initiative for Chronic Obstructive Lung Disease 2026."},{"issue":"10342","key":"3817_CR12","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227\u201342.","journal-title":"Lancet"},{"key":"3817_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/COPD.S36997","volume":"7","author":"MK Pasquale","year":"2012","unstructured":"Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulm Dis. 2012;7:757\u201364.","journal-title":"Int J Chron Obstruct Pulm Dis"},{"issue":"10","key":"3817_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/thx.2005.049940","volume":"61","author":"LC Price","year":"2006","unstructured":"Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts CM, et al. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006;61(10):837\u201342.","journal-title":"Thorax"},{"issue":"1","key":"3817_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2500\/aap.2015.36.3812","volume":"36","author":"SM May","year":"2015","unstructured":"May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015;36(1):4\u201310.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"3817_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101228","volume":"9","author":"F Blasi","year":"2014","unstructured":"Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS ONE. 2014;9(6):e101228.","journal-title":"PLoS ONE"},{"issue":"Suppl C","key":"3817_CR17","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0954-6111(03)80026-4","volume":"97","author":"JL Izquierdo","year":"2003","unstructured":"Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S61\u20139.","journal-title":"Respir Med"},{"key":"3817_CR18","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00141-2022","author":"JL Izquierdo","year":"2022","unstructured":"Izquierdo JL, Rodr\u00edguez JM, Almonacid C, Benavent M, Arroyo-Espliguero R, Agust\u00ed A. Real-life burden of hospitalisations due to COPD exacerbations in Spain. ERJ Open Res. 2022. https:\/\/doi.org\/10.1183\/23120541.00141-2022.","journal-title":"ERJ Open Res"},{"issue":"9","key":"3817_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/11535600-000000000-00000","volume":"28","author":"DW Mapel","year":"2010","unstructured":"Mapel DW, Schum M, Lydick E, Marton JP. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 2010;28(9):733\u201349.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3817_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semerg.2013.12.009","volume":"40","author":"JT G\u00f3mez S\u00e1enz","year":"2014","unstructured":"G\u00f3mez S\u00e1enz JT, Quintano Jim\u00e9nez JA, Hidalgo Requena A, Gonz\u00e1lez B\u00e9jar M, G\u00e9rez Callejas MJ, Zangr\u00f3niz Uru\u00f1uela MR, et al. Chronic obstructive pulmonary disease: morbimortality and healthcare burden. SEMERGEN. 2014;40(4):198\u2013204.","journal-title":"SEMERGEN"},{"key":"3817_CR21","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.2147\/COPD.S167357","volume":"13","author":"M Merino","year":"2018","unstructured":"Merino M, Villoro R, Hidalgo-Vega \u00c1, Carmona C. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulm Dis. 2018;13:2501\u201314.","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"3817_CR22","doi-asserted-by":"publisher","DOI":"10.37666\/L1-2015","volume-title":"Libro Blanco sobre la carga socio-econ\u00f3mica de la EPOC","author":"A Garc\u00eda","year":"2015","unstructured":"Garc\u00eda A, Hidalgo A, Rivera B, L\u00f3pez E, Esp\u00edn J, Oliva J, et al. Libro Blanco sobre la carga socio-econ\u00f3mica de la EPOC. Majadahonda: Instituto Max Weber; 2015."},{"key":"3817_CR23","unstructured":"Trixeo Aerosphere: Summary of Product Characteristics. European Medicines Agency; 2024."},{"issue":"12","key":"3817_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.arbres.2025.10.008","volume":"61","author":"M Miravitlles","year":"2025","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, G\u00f3mez JT, Trigueros JA, et al. Update 2025 of the Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol. 2025;61(12):766\u201382.","journal-title":"Arch Bronconeumol"},{"issue":"10","key":"3817_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3817_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"3817_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"3817_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106509","volume":"185","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M, et al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509.","journal-title":"Respir Med"},{"key":"3817_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211034329","volume":"15","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, et al. Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021;15:17534666211034329.","journal-title":"Ther Adv Respir Dis"},{"key":"3817_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2025.02.004","author":"A Hammadi","year":"2025","unstructured":"Hammadi A, Hoyas-S\u00e1nchez C, Romero-Linares A, \u00c1lvarez-Muro L, Men\u00e9ndez-Lobo A, Romeral-Navarro D, et al. All-cause and cardiovascular mortality with single inhaler triple therapy versus double therapies for COPD: a systematic review and metanalysis. Arch Bronconeumol. 2025. https:\/\/doi.org\/10.1016\/j.arbres.2025.02.004.","journal-title":"Arch Bronconeumol"},{"key":"3817_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/COPD.S452624","volume":"19","author":"H M\u00fcllerov\u00e1","year":"2024","unstructured":"M\u00fcllerov\u00e1 H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, et al. Budesonide\/glycopyrrolate\/formoterol for the management of COPD in a UK primary care population: real-world use and early medication success. Int J Chron Obstruct Pulm Dis. 2024;19:1153\u201366.","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"3817_CR32","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/COPD.S432963","volume":"18","author":"C Strange","year":"2023","unstructured":"Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, et al. Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide\/glycopyrrolate\/formoterol fumarate, among patients with COPD: results from the EROS (US) study. Int J Chron Obstruct Pulm Dis. 2023;18:2245\u201356.","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"3817_CR33","doi-asserted-by":"crossref","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et al. Abstract: Real-world safety of budesonide\/glycopyrrolate\/formoterol in Chinese patients with chronic obstructive pulmonary disease. In: 2024 ERS Congress: European Respiratory Journal; 2024. p. PA2999.","DOI":"10.1183\/13993003.congress-2024.PA2999"},{"key":"3817_CR34","doi-asserted-by":"crossref","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et al. Abstract: Effectiveness of budesonide\/glycopyrrolate\/formoterol fumarate in Chinese patients with chronic obstructive pulmonary disease in real-world clinical practice. In: CHEST 2024 annual meeting, Boston, Massachusetts, EE. UU: Elsevier; 2024. p. A4716\u2013A7.","DOI":"10.1016\/j.chest.2024.06.2841"},{"issue":"4","key":"3817_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2024.102418","volume":"51","author":"A Calder\u00f3n-Montero","year":"2025","unstructured":"Calder\u00f3n-Montero A, de Miguel Diez J, de Sim\u00f3n Guti\u00e9rrez R, Campos T\u00e9llez S, Chac\u00f3n Moreno AD, Alonso Avil\u00e9s R, et al. Triple inhaled therapy of formoterol\/glycopyrrolate\/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions. Med Fam SEMERGEN. 2025;51(4):102418.","journal-title":"Med Fam SEMERGEN"},{"key":"3817_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112681","author":"B Sposato","year":"2025","unstructured":"Sposato B, Lacerenza LG, Croce S, Petrucci E, Fabbrini V, Giannini L, et al. Real-life efficacy of single-inhaler triple therapy with budesonide\/glycopyrronium\/formoterol fumarate in persistent COPD users: a retrospective database study. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13112681.","journal-title":"Biomedicines"},{"issue":"5","key":"3817_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.resinv.2025.05.007","volume":"63","author":"S Muro","year":"2025","unstructured":"Muro S, Hozawa S, Sugiura H, Yoshida Y, Makita N, Kato Y, et al. Real-world effectiveness of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study. Respir Investig. 2025;63(5):726\u201333.","journal-title":"Respir Investig"},{"issue":"suppl 69","key":"3817_CR38","volume":"66","author":"H Watz","year":"2025","unstructured":"Watz H, Halbach M, Saathoff M, Morris T, Watt M, Fernandez Milano A, et al. Real-world outcomes of Budesonide\/Glycopyrronium\/Formoterol therapy in COPD after 12\u00a0months; the RECORD study. Eur Respir J. 2025;66(suppl 69):PA5697.","journal-title":"Eur Respir J"},{"key":"3817_CR39","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/COPD.S384591","volume":"17","author":"JA Trigueros","year":"2022","unstructured":"Trigueros JA, Garin N, Baloira A, Aceituno S, Calvo A, Prades M, et al. Cost-effectiveness analysis of triple therapy with budesonide\/ glycopyrronium\/ formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:2905\u201317.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3817_CR40","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/COPD.S381138","volume":"17","author":"E de Nigris","year":"2022","unstructured":"de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study. Int J Chron Obstruct Pulm Dis. 2022;17:2987\u20133000.","journal-title":"Int J Chron Obstruct Pulm Dis"},{"issue":"1","key":"3817_CR41","first-page":"4","volume":"8","author":"K Johnston","year":"2024","unstructured":"Johnston K, Shephard C, Friesen M, Azzalini C, Penz E. Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada. Can J Respir Crit Care Sleep Med. 2024;8(1):4\u201316.","journal-title":"Can J Respir Crit Care Sleep Med"},{"issue":"5","key":"3817_CR42","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40258-022-00732-1","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, He X, Wu J. Economic evaluation of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate for the treatment of moderate to very severe chronic obstructive pulmonary disease in China using a semi-Markov model. Appl Health Econ Health Policy. 2022;20(5):743\u201355.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"3817_CR43","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0111","volume":"15","author":"K Parsekar","year":"2026","unstructured":"Parsekar K, Pandey S, Tansey-Dwyer D, Marshall J, Rustignoli I, Pollack M, et al. Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease. J Comp Eff Res. 2026;15(1):e250111.","journal-title":"J Comp Eff Res"},{"key":"3817_CR44","unstructured":"United Nations. The Paris agreement. 2015."},{"key":"3817_CR45","unstructured":"OECD. Decarbonising health systems across OECD countries. Paris; 2025."},{"issue":"2","key":"3817_CR46","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2542-5196(20)30271-0","volume":"5","author":"I Tennison","year":"2021","unstructured":"Tennison I, Roschnik S, Ashby B, Boyd R, Hamilton I, Oreszczyn T, et al. Health care\u2019s response to climate change: a carbon footprint assessment of the NHS in England. Lancet Planet Health. 2021;5(2):e84\u201392.","journal-title":"Lancet Planet Health"},{"issue":"10211","key":"3817_CR47","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/S0140-6736(19)32596-6","volume":"394","author":"N Watts","year":"2019","unstructured":"Watts N, Amann M, Arnell N, Ayeb-Karlsson S, Belesova K, Boykoff M, et al. The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate. Lancet. 2019;394(10211):1836\u201378.","journal-title":"Lancet"},{"key":"3817_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02760-2021","author":"C Janson","year":"2022","unstructured":"Janson C, Maslova E, Wilkinson A, Penz E, Papi A, Budgen N, et al. The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.02760-2021.","journal-title":"Eur Respir J"},{"issue":"1","key":"3817_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/thoraxjnl-2019-213744","volume":"75","author":"C Janson","year":"2020","unstructured":"Janson C, Henderson R, L\u00f6fdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82\u20134.","journal-title":"Thorax"},{"issue":"5","key":"3817_CR50","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1007\/s12325-022-02076-7","volume":"39","author":"A Wilkinson","year":"2022","unstructured":"Wilkinson A, Maslova E, Janson C, Xu Y, Haughney J, Quint JK, et al. Environmental sustainability in respiratory care: an overview of the healthCARe-Based envirONmental cost of treatment (CARBON) programme. Adv Ther. 2022;39(5):2270\u201380.","journal-title":"Adv Ther"},{"key":"3817_CR51","unstructured":"Ministerio de Sanidad de Espa\u00f1a. Actuaciones para la evaluaci\u00f3n del impacto de la huella de carbono en centros sanitarios. 2023."},{"key":"3817_CR52","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 report). Global Initiative for Chronic Obstructive Lung Disease; 2025."},{"key":"3817_CR53","unstructured":"Collins M, Aum\u00f4nier S, Galley S, Archbold D. Care pathways: appraising sustainability. A life cycle assessment method document. Sustainable Healthcare Coalition; 2026."},{"key":"3817_CR54","unstructured":"Collins M, Aum\u00f4nier S, Galley S, Calnan A. Care pathways: guidance on appraising sustainability. Sustainable Healthcare Coalition; 2023."},{"issue":"5","key":"3817_CR55","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","volume":"162","author":"B Alc\u00e1zar-Navarrete","year":"2022","unstructured":"Alc\u00e1zar-Navarrete B, Jamart L, S\u00e1nchez-Covisa J, Ju\u00e1rez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022;162(5):1017\u201329.","journal-title":"Chest"},{"issue":"1","key":"3817_CR56","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12325-024-03039-w","volume":"42","author":"JJ Garcia Sanchez","year":"2025","unstructured":"Garcia Sanchez JJ, Barraclough KA, Cases A, Pecoits-Filho R, Germond-Duret C, Zoccali C, et al. Using chronic kidney disease as a model framework to estimate healthcare-related environmental impact. Adv Ther. 2025;42(1):348\u201361.","journal-title":"Adv Ther"},{"key":"3817_CR57","unstructured":"AstraZeneca, Federaci\u00f3n-ALCER. Descarbonizaci\u00f3n de las v\u00edas de atenci\u00f3n de la Enfermedad Renal Cr\u00f3nica (ERC) en Espa\u00f1a. AstraZeneca; 2025."},{"key":"3817_CR58","unstructured":"Direcci\u00f3n General de Tr\u00e1fico (DGT). Panel de Parque de veh\u00edculos en Espa\u00f1a (2024) [Internet]. Ministerio del Interior. https:\/\/paneldatos.dgt.es\/MicroStrategyLibraryGuest\/app\/A21CBE7011EC42DC71650080EF457DF5\/34900D0CAA457AEBCB3A5CA8A28A885A\/K3469807EE14C3C9F62E942BFF0ED0763--KC0BCB9BDC346CEBB2A5499A7DCE0B0D5. Accessed June 2026."},{"key":"3817_CR59","unstructured":"Ministerio para la Transici\u00f3n Ecol\u00f3gica y el Reto Demogr\u00e1fico. Factores de emisi\u00f3n 2007\u20132025. 2026."},{"key":"3817_CR60","unstructured":"Real Autom\u00f3vil Club de Espa\u00f1a (RACE) \u00bfCu\u00e1nta energ\u00eda consume un coche el\u00e9ctrico? : RACE; 2023. https:\/\/www.race.es\/cuanta-energia-consume-coche-electrico. Accessed June 2026."},{"issue":"6","key":"3817_CR61","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/ejhpharm-2024-004402","volume":"32","author":"N Garin","year":"2025","unstructured":"Garin N, Zarate-Tamames B, Lertxundi U, Martin da Silva I, Orive G, Crespo-Lessmann A, et al. The environmental impact of inhalers: a framework for sustainable prescription practices in Spain. Eur J Hosp Pharm. 2025;32(6):572\u20139.","journal-title":"Eur J Hosp Pharm"},{"key":"3817_CR62","first-page":"A38.2","volume":"77","author":"C Hargreaves","year":"2022","unstructured":"Hargreaves C, Budgen N, Whiting A, Lachacz K, Sommerville M, Archbell J, et al. S60 A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines. Thorax. 2022;77:A38.2\u2013A9.","journal-title":"Thorax."},{"issue":"1","key":"3817_CR63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.arbres.2025.06.003","volume":"62","author":"JJ Soler-Catalu\u00f1a","year":"2026","unstructured":"Soler-Catalu\u00f1a JJ, Villagrasa M, Catal\u00e1n P, Alc\u00e1zar-Navarrete B, Calle Rubio M, Miravitlles M. Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: the RADAR score. Arch Bronconeumol. 2026;62(1):28\u201334.","journal-title":"Arch Bronconeumol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03817-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:16:53Z","timestamp":1792599413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":63,"alternative-id":["3817"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03817-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Juan Marco Figueira-Gon\u00e7alves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Bernardino Alc\u00e1zar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Alba Ancochea, Teresa Lastres, Fernando de Andr\u00e9s-Nogales, Carmen Corregidor-Garc\u00eda, Eunice Fitas, and Joaqu\u00edn S\u00e1nchez-Covisa are employees of AstraZeneca.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ORESTES study was approved by the Ethics Committee of Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife, Spain) on 25 May 2024 (Minutes No. 05\/2024). The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulations for non-interventional observational studies. The requirement for written informed consent was waived by the Ethics Committee.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}